Evaluation of N-ratio in selecting patients for adjuvant chemoradiotherapy after d2-gastrectomy

Arq Gastroenterol. 2013 Oct-Dec;50(4):257-63. doi: 10.1590/S0004-28032013000400004.

Abstract

Context: Whether adjuvant chemoradiotherapy may contribute to improve survival outcomes after D2-gastrectomy remains controversial.

Objective: To explore the clinical utility of N-Ratio in selecting gastric cancer patients for adjuvant chemoradiotherapy after D2-gastrectomy.

Methods: A retrospective cohort study was carried out on gastric cancer patients who underwent D2-gastrectomy alone or D2-gastrectomy plus adjuvant chemoradiotherapy (INT-0116 protocol) at the Hospital A. C. Camargo from September 1998 to December 2008. Statistical analysis were performed using multiple conventional methods, such as c-statistic, adjusted Cox's regression and stratified survival analysis.

Results: Our analysis involved 128 patients. According to c-statistic, the N-Ratio (i.e., as a continuous variable) presented "area under ROC curve" (AUC) of 0.713, while the number of metastatic nodes presented AUC of 0.705. After categorization, the cut-offs provide by Marchet et al. displayed the highest discriminating power - AUC value of 0.702. This N-Ratio categorization was confirmed as an independent predictor of survival using multivariate analyses. There also was a trend of better survival by adding of adjuvant chemoradiotherapy only for patients with milder degrees of lymphatic spread - 5-year survival of 23.1% vs 66.9%, respectively (HR = 0.426, 95% CI 0.150-1.202; P = 0.092).

Conclusions: This study confirms the N-Ratio as a tool to improve the lymph node metastasis staging in gastric cancer and suggests the cut-offs provided by Marchet et al. as the best way for its categorization after a D2-gastrectomy. In these settings, the N-Ratio appears a useful tool to select patients for adjuvant chemoradiotherapy, and the benefit of adding this type of adjuvancy to D2-gastrectomy is suggested to be limited to patients with milder degrees of lymphatic spread (i.e., NR2, 10%-25%).

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / therapy*
  • Aged
  • Aged, 80 and over
  • Area Under Curve
  • Chemoradiotherapy, Adjuvant*
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Gastrectomy / methods
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / therapy*
  • Treatment Outcome